RDRiddha Das

Riddha Das

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Riddha Das has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lipid Nanoparticle‐mRNA Engineered Dendritic Cell Based Adoptive Cell Therapy Enhances Cancer Immune Response

    by Riddha Das, Xinying Ge, Fan Fei, Sepideh Parvanian, Ralph Weissleder, Christopher S. Garris

    Lipid nanoparticles encapsulating mRNA (LNP‐mRNA) revolutionized medicine over the past several years. While clinically approved indications currently focus on infectious disease vaccination, LNP‐mRNA based treatments also hold promise for cancer immunotherapy. However, the route of dosing may impact treatment efficacy, safety, and dose. To minimize adverse effects, it is hypothesized that LNP‐mRNA can be used to activate and engineer dendritic cells (DC) ex vivo before re‐administration of these cells. Here, it is shown that LNP‐mRNA engineered DCs can indeed vaccinate recipient mice. Vaccinated mice showed strong anti‐tumor T cell responses, rejected tumor challenge, and displayed no evidence of toxicity. Further, it is found that DC specific ablation of the immune activating kinase NFkB inducing kinase (NIK) abrogated vaccination efficacy, demonstrating that adoptively transferred DCs can be functionally modified in addition to their antigen presentation capacity. Collectively, these studies show that ex vivo LNP‐mRNA engineering of DCs is a feasible and robust therapeutic strategy for cancer.


  • Open Access

    Hybrid LNP Prime Dendritic Cells for Nucleotide Delivery

    by Riddha Das, Elias A. Halabi, Ina R. Fredrich, Juhyun Oh, Hannah M. Peterson, Xinying Ge, Ella Scott, Rainer H. Kohler, Christopher S. Garris, Ralph Weissleder

    The efficient activation of professional antigen‐presenting cells—such as dendritic cells (DC)—in tumors and lymph nodes is critical for the design of next‐generation cancer vaccines and may be able to provide anti‐tumor effects by itself through immune stimulation. The challenge is to stimulate these cells without causing excessive toxicity. It is hypothesized that a multi‐pronged combinatorial approach to DC stimulation would allow dose reductions of innate immune receptor‐stimulating TLR3 agonists while enhancing drug efficacy. Here, a hybrid lipid nanoparticle (LNP) platform is developed and tested for double‐stranded RNA (polyinosinic:polycytidylic acid for TLR3 agonism) and immune modulator (L‐CANDI) delivery. This study shows that the ≈120 nm hybrid nanoparticles‐in‐nanoparticles effectively eradicate tumors by themselves and generate long‐lasting, durable anti‐tumor immunity in mouse models.